Back to top
more

BioTechne Corp (TECH)

(Delayed Data from NSDQ)

$54.88 USD

54.88
1,847,280

-0.01 (-0.02%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $54.87 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Zacks Equity Research

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Zacks Equity Research

Should Vanguard SmallCap ETF (VB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VB

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Techne (TECH)

by Zacks Equity Research

Techne (TECH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

REGN vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

REGN vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Should SPDR S&P 400 Mid Cap Growth ETF (MDYG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MDYG

Zacks Equity Research

Should iShares Core S&P MidCap ETF (IJH) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJH

Zacks Equity Research

Techne (TECH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 3.39% and 1.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Should Vanguard SmallCap Growth ETF (VBK) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VBK

Zacks Equity Research

Should iShares S&P MidCap 400 Growth ETF (IJK) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJK

Zacks Equity Research

Should SPDR S&P MidCap 400 ETF (MDY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MDY

Zacks Equity Research

REGN or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

REGN vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Should SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPMD

Zacks Equity Research

Techne (TECH) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Techne (TECH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Is Techne (TECH) a Solid Growth Stock? 3 Reasons to Think " Yes "

by Zacks Equity Research

Techne (TECH) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

QIAGEN's (QGEN) Kits Hit New Milestone for Sample Preparation

by Zacks Equity Research

QIAGEN's (QGEN) consumables kits have been utilized to process more than 3 billion biological samples, emphasizing on its leading position in sample preparation.

Zacks Equity Research

Can Bio-Techne (TECH) Stock Continue to Grow Earnings?

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Bio-Techne (TECH).

Zacks Equity Research

Should SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPMD

Zacks Equity Research

QIAGEN (QGEN) Gains FDA's EUA for SARS CoV-2 Antigen Test

by Zacks Equity Research

QIAGEN's (QGEN) QIAreach SARS CoV-2 Antigen Test can detect SARS CoV-2 antigens in 2-15 minutes and can process an average of 30 swab samples per hour.

Zacks Equity Research

ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021. Shares down in after-hours trading.

Zacks Equity Research

Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the second quarter of 2021 while revenues miss estimates. Focus remains on the development of CRISPR gene-editing candidate, EDIT-101.

Zacks Equity Research

Techne (TECH) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 11.31% and 4.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Global Blood's (GBT) Q2 Earnings Beat, Revenues Rise Y/Y

by Zacks Equity Research

Global Blood (GBT) reports a narrower-than-expected loss in the second quarter of 2021 while its revenues also beat estimates.

Zacks Equity Research

Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

Vertex's (VRTX) earnings and sales beat estimates in the second quarter of 2021. The company raises revenue guidance for the year.